The Pharma Data

APRIL 19, 2022

Food and Drug Administration (FDA) has approved commercial production at the company’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer. About Gilead Sciences. Gilead Sciences, Inc.

FDA Approval 52

FDA Approval Therapies FDA Hospitals 52

The Pharma Data

JANUARY 14, 2021

Food and Drug Administration (FDA) approved Pfizer ’s Xalkori (crizotinib) for pediatric patients one year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. Manuel Esteban/Shutterstock.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

The Pharma Data

DECEMBER 18, 2020

FDA Approves Orgovyx (relugolix) as the First Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer. 18, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. BASEL, Switzerland, Dec.

FDA Approval 52

FDA Approval FDA Science Therapies 52

The Pharma Data

MAY 27, 2022

Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah ® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

FDA Approval 52

FDA Approval Therapies FDA Treatment 52

FDA Law Blog: Biosimilars

AUGUST 21, 2023

Livornese — I saw the sign…and the answer is no—FDA-approved labeling apparently is not enough under state failure-to-warn laws, according to certain courts. Brand drugs, generic drugs, and medical devices alike have all been the target of state failure-to-warn litigation; in a recent case, OTC acetaminophen is the target.

FDA Approval 40

FDA Approval FDA Production Drugs 40

The Pharma Data

NOVEMBER 15, 2020

In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma. Vibegron also showed favorable longer-term efficacy, safety, and tolerability in a 40-week extension study. . Urovant shareholders will receive $16.25 Source link.

Science 52

Science Small Molecule FDA Approval Therapies 52

Codon

JULY 14, 2024

receives a blood transfusion or a blood product every two seconds. But currently, traditional blood transfusions face significant challenges, including a dwindling pool of donors and a limited shelf life for stored blood products. According to the American Red Cross, someone in the U.S. to the European and Pacific fronts unfeasible.

Production 138

Production Clinical Trials Trials Therapies 138

The Pharma Data

JANUARY 15, 2021

Food and Drug Administration (FDA) approval of Darzalex Faspro ® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1]

FDA Approval 52

FDA Approval Treatment FDA Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 6, 2020

Basel, 7 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

FDA Law Blog: Biosimilars

NOVEMBER 5, 2023

The 14th Asia Pacific Symposium on Cochlear Implant and Related Sciences is poised to captivate the global scientific community from November 8-11, 2023, as it convenes in Seoul, Korea. The comprehensive agenda for the symposium can be accessed in its entirety here.

Science 52

Science FDA Approval FDA Regulations 52

The Pharma Data

JULY 29, 2021

econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Gilead Sciences, Inc. Our flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.

Science 52

Science Production Treatment FDA 52

The Pharma Data

MAY 6, 2022

The booster schedule is based on the labeling information of the vaccine used for the primary series COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.

FDA Approval 52

FDA Approval Licensing Licensing FDA 52

Eye on FDA

AUGUST 4, 2021

As more drugs are being approved, is FDA getting less advice than in the past? FDA maintains a vast network of outside advisors to provide input and counsel to the agency related to decisions on policy as well as product approvals.

FDA 122

FDA Clinical Pharmacology FDA Approval Therapies 122

The Pharma Data

JANUARY 6, 2021

Jinhan Kim, co-founder and CEO of Standigm said, “Partnering with SK Group has been incredibly productive. SK Chemicals is a leading company in the fields of chemistry and life science. We look forward to announcing AI-aided new drug candidates as well as more AI-driven repurposed drug candidates.”

FDA Approval 52

FDA Approval FDA Drugs Science 52

The Pharma Data

OCTOBER 22, 2020

With today’s FDA approval, and regulatory approvals or temporary authorizations in approximately 50 additional countries around the world, Veklury® (remdesivir) is one of the tools available today. Source: Gilead Sciences, Inc. . Related Articles: Veklury (remdesivir) FDA Approval History. N Engl J Med.

Science 52

Science Clinical Trials Hospitals Trials 52

EG Life Sciences

FEBRUARY 15, 2023

Every year, the FDA’s Center for Drug Evaluation and Research (CDER) clarifies to drug developers required study design elements, as well as other data needed on the drug application to support a full and comprehensive assessment. The US Food and Drug Administration (FDA) approved around 26 novel drugs in 2022.

Drug Development 52

Drug Development FDA Approval Drugs Virus 52

KIF1A

JULY 1, 2023

In science, aligning mathematical models with experimental observations improves our understanding of the underlying biology. Taking a drug that shelved during development or didn’t receive FDA approval, and assessing its application for another disease, is called drug repositioning. What’s a pre-print?

Small Molecule 98

Small Molecule FDA Approval Disease Pharmaceutical Companies 98

DrugBank

MAY 6, 2024

A Wave of Innovations The year 2024 has already proven to be significant for the field of biologics, witnessing a notable increase in FDA approvals. In the first quarter alone, the FDA approved 9 new biologics, a substantial rise from the 5 approvals during the same period in 2023.

FDA Approval 65

FDA Approval Therapies Treatment Clinical Trials 65

Agency IQ

OCTOBER 20, 2023

BsUFA III regulatory science pilot offers progress report, fields stakeholder criticisms and questions This week, FDA and its grantees briefed stakeholders on the status of research projects funded through the Biosimilar User Fee Act (BSUFA III) Regulatory Science Pilot Program.

Science 40

Science Biosimilars FDA Production 40

The Pharma Data

JULY 29, 2021

“This label expansion not only adds to our rich history in neurotoxin science, but also reinforces the role of BOTOX ® in upper limb spasticity treatment. BOTOX ® was first approved by the FDA in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults. About BOTOX ®. Source link: [link].

FDA Approval 52

FDA Approval FDA Doctors Clinical Trials 52

The Pharma Data

OCTOBER 29, 2020

NASDAQ: REGN ) today announced that the company was once again ranked as the top company to work for by Science magazine in its annual Top Employers Survey of the global biotech and pharmaceutical industry. The rankings are available in the print issue of Science and at [link]. . Regeneron Pharmaceuticals, Inc. Schleifer , M.D.,

Science 40

Science FDA Approval Pharmaceuticals Disease 40

The Pharma Data

JANUARY 6, 2021

CytoDel” or “the Company”), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. . NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) — CytoDel, Inc. Südhof, M.D.,

Science 52

Science Molecular Biology Treatment Production 52

The Pharma Data

FEBRUARY 25, 2022

The PAS was supported by positive topline data from the REFLECTIONS B538-12 study which evaluated multiple switches between treatment with ABRILADA and its reference product, Humira, both of which were administered with methotrexate in adult patients with moderate to severe rheumatoid arthritis (RA).

Biosimilars 52

Biosimilars FDA FDA Approval Small Molecule 52

Drug Target Review

MAY 15, 2024

3 The value required is more than just a greater number of FDA approvals, it is also about completing milestones with limited capital – ie, biotech survival. The latter group (ie, most of us) are waiting for wet lab validation, market demonstration (FDA approvals), and a few other things (which we often cannot define).

FDA Approval 59

FDA Approval FDA Science Marketing 59

FDA Law Blog: Biosimilars

FEBRUARY 27, 2024

156, a patent may be extended only once (even if it would be eligible for extension on more than one occasion because it applies to several FDA-approved products), and only one patent may be extended for each regulatory review period. FDA-2020-E-1840 (July 13, 2020). To that end, 35 U.S.C. § 156(c)(4) 351, 355-56 (1985).

FDA Approval 59

FDA Approval FDA Production Therapies 59

Agency IQ

OCTOBER 6, 2023

As such, it doesn’t review things like vaccines, blood products or gene therapies – those products are instead reviewed by CBER. All products are received in one of two forms: A New Drug Application (or NDA, for pharmaceuticals) or a Biologics License Application (BLA, for biologics).

FDA 52

FDA Biosimilars Science Production 52

Broad Institute

OCTOBER 11, 2023

As a first step, Manguso set his sights on treatments called PD-1 checkpoint inhibitors, which at the time had shown tremendous promise in clinical trials and would receive their first FDA approval in 2014. Along the way, TIDE is showing how careful, systematic science at scale can quickly home in on promising drug targets.

Research 137

Research Immune Response Clinical Trials Therapies 137

The Pharma Data

JANUARY 21, 2021

NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in the Regeneron Science Talent Search 2021, the nation’s oldest and most prestigious science and math competition for high school seniors. ” Regeneron Science Talent Search 2021 Fast Facts. Regeneron Pharmaceuticals, Inc.

Science 40

Science Engineering Molecular Biology Bioinformatics 40

The Pharma Data

OCTOBER 22, 2021

The company’s success in rephrasing exploration and development ( R&D) leadership into discerned and advanced products for growers is driving functional performance, while shaping the future of husbandry. The company is also seeing increased deals of its own products among FieldView ™ druggies. added Condon. “ and Brazil alone.

FDA Approval 52

FDA Approval FDA Production Trials 52

The Pharma Data

DECEMBER 16, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Laboratories Disease Pharmaceuticals 52

The Pharma Data

JANUARY 19, 2021

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Laboratories Disease Pharmaceuticals 52

The Pharma Data

NOVEMBER 30, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Laboratories Disease Pharmaceuticals 52

The Pharma Data

OCTOBER 27, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Laboratories Disease Pharmaceuticals 52

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues. Asia, and Europe.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Agency IQ

JUNE 7, 2024

BY CHELSEY MCINTYRE, PHARMD | JUN 3, 2024 8:43 PM CDT Regulatory background: DSHEA and dietary supplements The Dietary Supplement Health and Education Act ( DSHEA ) of 1994 defines the FDA’s authority in the regulation of dietary supplement products and dietary ingredients. See AgencyIQ’s analysis of the draft guidance here. ]

FDA 40

FDA Science Production FDA Approval 40

Agency IQ

JANUARY 4, 2024

Now, the FDA has released guidance laying out the tests and regulatory submissions needed for the reformulation of products containing these ingredients. Benzene may occur in some products from the degradation of other ingredients, increasing the risk for unintentional contamination.

FDA 40

FDA Production Laboratories Drugs 40

PLOS: DNA Science

JANUARY 4, 2024

The end-of-year FDA approval of the first CRISPR-based therapy , for sickle cell disease, came a mere dozen years after Jennifer Doudna and Emmanuelle Charpentier introduced the technology. One of the first FDA-approved gene therapies was to treat LCA2, another form of retinal blindness. It restores vision in just days.

FDA Approval 52

FDA Approval DNA Therapies Clinical Trials 52